TruthArchive.ai - Related Video Feed

Thanks to the Biden administration and Dr. Fauci, millions of children have been vaccinated. If you're still considering it, get informed by talking to your family doctor, pediatrician, or school nurse. They'll confirm it's safe and effective, and tailored for kids. Visit vaccine.gov to find a free vaccination location. Get vaccinated for your kids, your family, and the community.

We are making this dream a reality with this announcement. The COVID vaccine has proven to be highly effective, although its logistics were complex due to the new technology.

Speaker 0 asked for the impossible: to develop a vaccine in 8 months instead of 10 years without cutting corners. They emphasized safety. Speaker 1 questioned Pfizer's transparency in mutating COVID viruses. Speaker 0 stressed the importance of vaccination for public health. Pfizer's CEO discussed vaccine production and effectiveness. They thanked the US government for support. The CEO highlighted the vaccine's 95.6% efficacy. The conversation ended with a call for public vaccination.

Vaccines are seen as magical but expectations should be tempered. Pfizer's vaccine is 95% effective, but efficacy drops over time. Boosters may be needed annually. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but we must adapt.

Pfizer announced its vaccine trial for 12-15 year olds was 100% effective in preventing infection. This news could impact school reopenings. Dr. Purnell, a public health physician, noted the mRNA vaccine technology is promising, with efficacy rates even higher than in adults. The 100% effectiveness is unprecedented and a significant development.

The AstraZeneca vaccine is 100% effective against hospitalization and death, a crucial statistic that needs more attention. This information has only recently become available, and while the 70% effectiveness rate is also impressive, the focus should be on the strong protection it offers against severe outcomes.

There is a new mRNA COVID-19 vaccine, but there is no evidence to support its effectiveness or safety in human trials. Additionally, several studies from different countries suggest that these vaccines may actually increase the risk of contracting COVID-19 over time. This is concerning and not a typical outcome.

Vaccinating kids before the next school year is realistic. A study with around 1,200 adolescents showed no COVID cases in the vaccinated group, indicating high efficacy. Vaccinating adolescents is crucial, especially as some are being hospitalized, particularly those with underlying conditions. To effectively interrupt virus transmission, we need 80-85% vaccination coverage, which can be achieved by including adolescents. This will lead to a safer school year for students and staff. However, there will be challenges in public acceptance, as some parents may be hesitant about the new mRNA technology. Ongoing communication and advocacy will be essential to address concerns and encourage vaccination, which is expected to increase over time as more kids get vaccinated without adverse effects.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

Dr. Menares and an interlocutor debate the science behind pediatric COVID vaccination and routine immunizations, focusing on transmission, hospitalization, and risk. - The interlocutor asks whether the COVID vaccine prevents transmission. Speaker 1 answer: the vaccine can reduce viral load in individuals who are infected, and with reduced viral load, there is reduced transmission. The interlocutor reframes, insisting that the vaccine does not prevent transmission and notes decreasing effectiveness over time, citing Omicron data showing around 16% reduction when there is a reduction. - On hospitalization for children 18 and under: Speaker 0 asserts the vaccine does not reduce hospitalization for 18-year-olds; statistics are inconclusive due to small numbers of hospitalizations in that age group (approximately 76 million people aged 18 in the country, with 183 deaths and a few thousand hospitalizations in 2020–2021; numbers have since dropped). The argument emphasizes a need to discuss the issue. - On death for children 18 and under: Speaker 0 says the vaccine does not reduce the death rate; claims there is no statistical evidence that it reduces deaths. Speaker 1 responds with a more cautious stance: “It can,” but Speaker 0 counters, calling that an insufficient answer. - The discussion references the vaccine approval process and ongoing debates in vaccine committees. The interlocutor states that when the vaccine was approved for six months and older, the discussion acknowledged no proof of reduction in hospitalization or death. The argument asserts that the justification for vaccination is based on antibody generation rather than clear hospitalization/death data. The interlocutor contends that immunology measurements (antibody production) do not necessarily justify vaccination frequency. - The core debate centers on what the science supports for vaccinating six-month-olds and the benefits versus risks. The interlocutor argues there is no hospitalization or death benefit for vaccination in this age group, and notes a known risk of myocarditis in younger populations, estimated somewhere between six and ten per ten thousand, which the interlocutor claims is greater than the risk of hospitalization or death being measurable. - The exchange then shifts to changing the childhood vaccine schedule, particularly the hepatitis B vaccine given to newborns when the mother is not hepatitis B positive. The interlocutor asks for the medical or scientific reason to give a hepatitis B vaccine to a newborn with an uninfected mother, arguing that the discussion should focus on whether to change the schedule rather than declaring all vaccines as good or bad. - Speaker 1 says they agreed with considering the science and would not pre-commit to approving all ACIP recommendations without the science. Speaker 0 disagrees, asserting their position that the debate should center on the medical rationale for these specific vaccines and schedules, not on a blanket endorsement of vaccines. - Throughout, the dialogue emphasizes examining the medical reasons and evidence for specific vaccines and schedules, rather than broad generalizations about vaccines.

We achieved over 90% efficacy with our vaccine, providing protection against all identified variants, including the challenging South African variant. Studies in South Africa showed 100% efficacy. While two doses offer limited protection against Omicron, three doses are effective against hospitalizations and deaths. A fourth booster may be needed. The Pfizer COVID vaccine was not tested for stopping transmission before market release. No serious adverse events were found in our data analysis. Lawsuits have been filed against Pfizer for alleged misrepresentation of vaccine effectiveness and safety concerns. The success of our vaccine is a significant scientific breakthrough.

The COVID-19 vaccines have proven to be highly effective in the real world. Both the mRNA vaccine and another vaccine have shown efficacy rates of 94% to 95% for mild to moderate disease. In fact, the real world effectiveness of these vaccines is even more impressive than the results of the clinical trials. It is clear that these vaccines are highly effective in preventing COVID-19.

COVID-19 vaccines are described as safe and effective for various age groups, including children as young as five. Pfizer, Moderna, AstraZeneca, and Johnson & Johnson vaccines are highlighted. Studies and trials have confirmed the vaccines' safety and efficacy, with some showing high effectiveness in preventing symptomatic infections and severe disease. The FDA and European Medicines Agency have assessed and approved these vaccines. A booster shot different from the original vaccination is likely safe and effective. The vaccines are considered a key tool, along with mask-wearing and social distancing, to combat the spread of COVID-19 and return to normalcy.

Moderna and Pfizer discuss vaccine effectiveness. Various incentives for vaccination are mentioned. The importance of vaccination is emphasized to prevent overcrowding in hospitals. Calls for shaming those who refuse vaccines are made. Boosters are encouraged. Vaccinated individuals do not spread the virus. Vaccination is seen as crucial for ending the pandemic. Refusal to vaccinate is criticized for impacting everyone.

From what we learned, Lisa discusses the mediation of COVID vaccines. It seems that there is a vaccine available, and it is highly effective.

Vaccines are seen as magical, but expectations may need to be lowered. Pfizer's vaccine is 95% effective, but efficacy rates can fluctuate. Protection may only last a year, requiring annual shots. Moderna is working on a combined flu and COVID vaccine. The future is uncertain, but there is hope for improvement in the next 5 years.

Safe and effective vaccines have been developed and millions of doses are being delivered. The vaccines have been rigorously studied and proven to be safe and effective. Researchers have confirmed the safety and efficacy of various vaccines, including the Oxford AstraZeneca and Pfizer COVID-19 vaccines. Vaccination has been deemed safe and effective for children, with Pfizer's vaccine being 100% effective for kids aged 5 to 11. The European Medicines Agency has thoroughly assessed the vaccines and concluded they are safe and effective against COVID-19. The vaccines have undergone extensive testing and have been found to be extremely safe and effective. Overall, vaccines are considered safe, effective, and free.

Children aged 5 to 11 can now get the COVID vaccine to protect older and vulnerable individuals. The vaccine has low side effects, with only a few cases of heart inflammation out of millions vaccinated in the US. Getting COVID poses a higher risk of heart inflammation than the vaccine. Vaccinating kids can reduce school disruptions and help safeguard older people.

Europe is considering extending vaccination authorization to children as young as 12. France is also expected to follow suit. The paradigm is shifting from protecting the most vulnerable to preventing virus transmission. Vaccines not only prevent severe cases but also transmission. The results of Pfizer's vaccine trials in adolescents have shown good efficacy and tolerance. Therefore, it is crucial to vaccinate those who are most likely to transmit the virus, including teenagers. Vaccination for 12 to 18-year-olds should be available by the latest at the start of the school year, and hopefully even sooner.

A study of 1,700,000 children found heart damage only in COVID-vaccinated children, with zero heart-related problems in unvaccinated children. The study also found that no children, vaccinated or unvaccinated, died from COVID-19. The COVID shots offered little protection, with many children becoming infected after 14-15 weeks. The study, led by Oxford University's Professor Kome d Andrews, investigated Pfizer's vaccine safety and effectiveness in 5-15 year olds registered with the UK's national healthcare system. Myocarditis and pericarditis cases only emerged in the vaccinated group. The speaker asserts emergency use authorization was given despite evidence the injections were not safe, which Pfizer and the FDA allegedly knew. The speaker claims future injection rollouts need more scrutiny and alleges globalists plan to force regular injections via digital ID systems to prevent future pandemics. The speaker urges scrutiny of everything from big pharma.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

The speaker acknowledges that the vaccine did not completely stop the spread or infection, but clarifies that initially it did for the Wuhan strain and the alpha strain. Early data and literature published in the New England Journal showed that those who were vaccinated and didn't get infected were not transmitting the virus to others. The vaccine had a high efficacy of up to 96% early on and this efficacy did not change over time.

Pfizer has announced that its coronavirus vaccine trial for adolescents aged 12 to 15 showed 100% effectiveness in preventing infection and illness. This significant finding could greatly impact the reopening of schools in America. Doctor Chris Purnell, a public health physician, noted that this efficacy rate is even higher than the 95% reported for adults. She emphasized that mRNA vaccines represent a groundbreaking advancement in technology, highlighting the promising results of the trial.